

# ● PRINTER RUSH ●

(PTO ASSISTANCE)

2nd Query

Application: 09916849 Examiner: Carroll GAU: 1542  
From: J. Black Location: IDC FMF FDC Date: 1/20/06

Tracking #: 06125539 Week Date: 7/18/05  
Attn. Chief Draftsperson

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449		<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS		<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM		<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW		<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW		<input type="checkbox"/> Other
<input type="checkbox"/> DRW		
<input type="checkbox"/> OATH		
<input type="checkbox"/> 312		
<input checked="" type="checkbox"/> SPEC	<u>7/26/01</u>	

## [RUSH] MESSAGE:

The specification does not contain a paragraph referring to colored drawings as required per 37 CFR 1.84 (a)(2)(iv).

Please resolve.

## [XRUSH] RESPONSE:

ATTACHED IS THE PARAGRAPH FOR COLOR PHOTOS IN WHICH IS TO BE INSERTED INTO THE SPECIFICATIONS UNDER THE BRIEF DESCRIPTION

INITIALS: JDC

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04

above for identifying compounds and (ii) a second compound, wherein the second compound is approved by the U.S. Food and Drug administration for the treatment of cancer or has shown potential efficacy against cancer in pre-clinical studies. The invention also provides a pharmaceutical composition comprising such a composition and a pharmaceutically acceptable carrier.

The present application refers to various patents, publications, books, articles, and other references. The contents of all of these items are hereby incorporated by reference in their entirety. The present application also incorporates by reference six U.S. patent applications filed by inventors on July 26, 2001. These applications are entitled "REAGENTS AND METHODS FOR USE IN MANAGING BREAST CANCER", "BSTP-RAS/RERG PROTEIN AND RELATED REAGENTS AND METHODS OF USE THEREOF", "BSTP-ECG1 PROTEIN AND RELATED REAGENTS AND METHODS OF USE THEREOF", "BSTP-CAD PROTEIN AND RELATED REAGENTS AND METHODS OF USE THEREOF", "BSTP-TRANS PROTEIN AND RELATED REAGENTS AND METHODS OF USE THEREOF", "BSTP-5 PROTEINS AND RELATED REAGENTS AND METHODS OF USE THEREOF".

SEE ATTACHMENT } BRIEF DESCRIPTION OF THE DRAWING

Figure 1A presents the amino acid sequence of the polypeptide encoded by the basal marker gene known as cadherin 3 or P-cadherin (SEQ ID NO:1).

Figure 1B presents the amino acid sequence of the polypeptide encoded by the basal marker gene known as matrix metalloproteinase 14 (SEQ ID NO:2).

Figure 1C presents the amino acid sequence of the polypeptide encoded by the basal marker gene known as cadherin EGF LAG seven-pass G-type receptor 2 or EGF-Like Domain, Multiple 2 (SEQ ID NO:3).

Figure 1D presents the amino acid sequences of peptides used to raise antibodies that recognize the cadherin 3, matrix metalloproteinase 14, cadherin EGF LAG seven-pass G-type receptor 2, and cytokeratin 17 proteins.

Figure 2 shows a comparison of dendrograms representing the results of hierarchical clustering of experimental samples using the intrinsic gene set and the epithelial-enriched gene set.

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.